Faculty Collaboration Database

Clinical experience with topiramate dosing and serum levels in children 12 years or under with epilepsy. J Child Neurol 2001 Nov;16(11):806-8

Date

12/06/2001

Pubmed ID

11732765

DOI

10.1177/08830738010160110501

Scopus ID

2-s2.0-0035215871 (requires institutional sign-in at Scopus site)   9 Citations

Abstract

Only a limited topiramate dosing range (5-9 mg/kg/day) is approved by the U.S. Food and Drug Administration (FDA). We reviewed our topiramate dosing (mg/kg/d) and corresponding serum levels (microg/mL) (n = 77) in 41 children who were treated to clinical response or tolerability. The patients were divided into older (6-12 years [n = 21]) and younger (< or = 5 years [n = 20]) groups. Topiramate was given as monotherapy (n = 9), with an enzyme-inducing antiepileptic drug (n = 16) (phebarbital, phenytoin, or carbamazepine), or as polytherapy (n =17) (another antiepileptic drug). In the older children, there was a good dosage to serum level correspondence. However, younger children on topiramate monotherapy or cotherapy with an enzyme-inducing antiepileptic drug had relatively lower serum levels, but the serum level was increased if they were on polytherapy without an enzyme-inducing drug. This study supports a wider dosing range (7-22 mg/kg/day) of topiramate and dosage escalation beyond the approved range. Serum levels are useful in guiding topiramate dosing, especially in young children.

Author List

Schwabe MJ, Wheless JW

MESH terms used to index this publication - Major topics in bold

Anticonvulsants
Child
Drug Monitoring
Epilepsy
Female
Fructose
Humans
Infant
Male